Concordance of DNA mismatch repair deficient (dMMR)/microsatellite instability (MSI) assessment by local and central testing in patients with metastatic CRC (mCRC) receiving nivolumab (nivo) in CheckMate 142 study.

被引：4
|
作者：
Kopetz, Scott
Lonardi, Sara
McDermott, Raymond S.
Aglietta, Massimo
Hendlisz, Alain
Morse, Michael
Leach, Joseph W.
Neyns, Bart
Chan, Emily
Chen, Franklin
Wong, Ka Yeung Mark
Lee, James J.
Garcia-Alfonso, Pilar
Hill, Andrew G.
Lenz, Heinz-Josef
Desai, Jayesh
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷
关键词：
D O I：
10.1200/JCO.2017.35.15_suppl.3548
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3548
引用
收藏
页数：5
相关论文
共 50 条
  • [21] Nivolumab plus relatlimab in patients with previously treated microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: the phase II CheckMate 142 study
    Overman, Michael J.
    Gelsomino, Fabio
    Aglietta, Massimo
    Wong, Mark
    Limon Miron, Maria Luisa
    Leonard, Gregory
    Garcia-Alfonso, Pilar
    Hill, Andrew G.
    Cubillo Gracian, Antonio
    Van Cutsem, Eric
    El-Rayes, Bassel
    McCraith, Stephen M.
    He, Beilei
    Lei, Ming
    Lonardi, Sara
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2024, 12 (05)
  • [22] Durable clinical benefit with nivolumab (NIVO) plus low-dose ipilimumab (IPI) as first-line therapy in microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC)
    Lenz, H-J. J.
    Van Cutsem, E.
    Limon, M. L.
    Wong, K. Y.
    Hendlisz, A.
    Aglietta, M.
    Garcia-Alfonso, P.
    Neyns, B.
    Luppi, G.
    Cardin, D.
    Dragovich, T.
    Shah, U.
    Atasoy, A.
    Postema, R.
    Boyd, Z.
    Ledeine, J-M.
    Overman, M.
    Lonardi, S.
    ANNALS OF ONCOLOGY, 2018, 29 : 714 - 714
  • [23] Potential drug cost impact of nivolumab (N) in Canada in patients with DNA mismatch repair deficient (dMMR) metastatic colorectal cancer (mCRC)
    Virik, Kiran
    Biagi, James Joseph
    Wilson, Robert B.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [24] SYSTEMATIC AND STRUCTURED REVIEWS OF THE DISEASE BURDEN IN PATIENTS WITH MICROSATELLITE INSTABILITY HIGH (MSI-H) OR MISMATCH REPAIR DEFICIENT (DMMR) COLORECTAL CANCER (CRC)
    Amonkar, M.
    Chase, M.
    Takyar, J.
    Sharma, S.
    VALUE IN HEALTH, 2021, 24 : S24 - S24
  • [25] Nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) as first-line (1L) treatment for microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): First results of the CheckMate 8HW study
    Andre, Thierry
    Elez, Elena
    Van Cutsem, Eric
    Jensen, Lars Henrik
    Bennouna, Jaafar
    Mendez, Guillermo
    Schenker, Michael
    De La Fouchardiere, Christelle
    Limon, Maria Luisa
    Yoshino, Takayuki
    Li, Jin
    Lenz, Heinz-Josef
    Manzano Mozo, Jose Luis
    Tortora, Giampaolo
    Garcia-Carbonero, Rocio
    Cela, Elvis
    Yang, Yingsi
    Lei, Ming
    Jin, Lixian
    Lonardi, Sara
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : LBA768 - LBA768
  • [26] ONCOLOGISTS' PERCEPTIONS OF NIVOLUMAB PLUS IPILUMUMAB (NIVO plus IPI) AS FIRST-LINE (1L) TREATMENT FOR MICROSATELLITE INSTABILITY-HIGH/MISMATCH REPAIR-DEFICIENT (MSI-H/DMMR) METASTATIC COLORECTAL CANCER (MCRC)
    Emidio, O.
    Iqbal, Z.
    Jeune-Smith, Y.
    Feinberg, B.
    VALUE IN HEALTH, 2024, 27 (12) : S351 - S351
  • [27] Nivolumab (NIVO) plus low-dose ipilimumab (IPI) as first-line (1L) therapy in microsatellite instability-high/DNA mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Clinical update.
    Lenz, Heinz-Josef
    Lonardi, Sara
    Zagonel, Vittorina
    Van Cutsem, Eric
    Limon, M. Luisa
    Wong, Ka Yeung Mark
    Hendlisz, Alain
    Aglietta, Massimo
    Garcia-Alfonso, Pilar
    Neyns, Bart
    Cardin, Dana Backlund
    Spallanzani, Andrea
    Dragovich, Tomislav
    Shah, Usman
    Atasoy, Ajlan
    Ledeine, Jean-Marie
    Overman, Michael J.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [28] Prevalence of NTRK1/3 fusions in mismatch repair-deficient (dMMR)/microsatellite instable (MSI) tumors of patients with metastatic colorectal cancer (mCRC).
    Svrcek, Magali
    Colle, Raphael
    Cayre, Anne
    Bourgoin, Pierre
    Cohen, Romain
    Andre, Thierry
    Penault-Llorca, Frederique Madeleine
    Radosevic-Robin, Nina
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [29] Nivolumab (NIVO) plus low-dose ipilimumab (IPI) in previously treated patients (pts) with microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Long-term follow-up.
    Overman, Michael J.
    Lonardi, Sara
    Wong, Ka Yeung Mark
    Lenz, Heinz-Josef
    Gelsomino, Fabio
    Aglietta, Massimo
    Morse, Michael
    Van Cutsem, Eric
    McDermott, Raymond S.
    Hill, Andrew G.
    Sawyer, Michael B.
    Hendlisz, Alain
    Neyns, Bart
    Svrcek, Magali
    Atasoy, Ajlan
    Zhao, Huanyu
    Lei, Ming
    Kopetz, Scott
    Andre, Thierry
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
  • [30] KNOWLEDGE AND AWARENESS OF MISMATCH REPAIR/MICROSATELLITE INSTABILITY (MMR/MSI) TESTING AMONG US PATIENTS WITH ADVANCED/METASTATIC COLORECTAL CANCER (MCRC)
    Eriksson, J.
    Amonkar, M.
    Al-Jassar, G.
    Lambert, J.
    Malmenas, M.
    Chase, M.
    Sun, L.
    Kollmar, L.
    Vichnin, M.
    VALUE IN HEALTH, 2019, 22 : S110 - S110
12345